| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 98 | 2023 | 3290 | 8.710 |
Why?
|
| Anticonvulsants | 45 | 2020 | 1906 | 2.980 |
Why?
|
| Seizures | 34 | 2022 | 2957 | 2.530 |
Why?
|
| Epilepsies, Partial | 20 | 2022 | 431 | 1.790 |
Why?
|
| Vagus Nerve Stimulation | 6 | 2022 | 228 | 1.630 |
Why?
|
| Electroencephalography | 34 | 2022 | 6237 | 1.370 |
Why?
|
| Vagus Nerve | 11 | 2006 | 458 | 1.200 |
Why?
|
| Art | 4 | 2016 | 64 | 1.150 |
Why?
|
| Electric Stimulation Therapy | 12 | 2014 | 628 | 1.000 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2022 | 2244 | 0.950 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2018 | 448 | 0.890 |
Why?
|
| Sesquiterpenes | 9 | 2017 | 176 | 0.850 |
Why?
|
| Epilepsy, Temporal Lobe | 5 | 2017 | 389 | 0.790 |
Why?
|
| Functional Laterality | 12 | 2017 | 2257 | 0.750 |
Why?
|
| Implantable Neurostimulators | 2 | 2018 | 75 | 0.730 |
Why?
|
| Behavior | 3 | 2013 | 541 | 0.710 |
Why?
|
| Nipecotic Acids | 8 | 2004 | 36 | 0.710 |
Why?
|
| Publications | 1 | 2022 | 194 | 0.700 |
Why?
|
| Alkaloids | 9 | 2017 | 192 | 0.680 |
Why?
|
| Carbamazepine | 10 | 2020 | 224 | 0.670 |
Why?
|
| Self-Help Devices | 1 | 2020 | 62 | 0.660 |
Why?
|
| Signal Processing, Computer-Assisted | 7 | 2012 | 1496 | 0.600 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2019 | 578 | 0.600 |
Why?
|
| Memantine | 1 | 2018 | 108 | 0.590 |
Why?
|
| Death, Sudden | 4 | 2022 | 301 | 0.580 |
Why?
|
| Heart Rate | 9 | 2023 | 4195 | 0.570 |
Why?
|
| Long QT Syndrome | 1 | 2022 | 467 | 0.570 |
Why?
|
| Epilepsy, Generalized | 7 | 2021 | 178 | 0.550 |
Why?
|
| Patient Advocacy | 1 | 2019 | 360 | 0.540 |
Why?
|
| Quality of Life | 16 | 2020 | 13367 | 0.530 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 610 | 0.520 |
Why?
|
| Practice Management | 1 | 2016 | 37 | 0.520 |
Why?
|
| Mind-Body Therapies | 2 | 2017 | 279 | 0.510 |
Why?
|
| Magnetic Field Therapy | 1 | 2015 | 27 | 0.490 |
Why?
|
| Electrocardiography | 10 | 2023 | 6377 | 0.470 |
Why?
|
| Conflict of Interest | 1 | 2019 | 554 | 0.450 |
Why?
|
| Humans | 173 | 2023 | 761596 | 0.450 |
Why?
|
| Health Communication | 1 | 2016 | 213 | 0.440 |
Why?
|
| Dominance, Cerebral | 6 | 1996 | 623 | 0.440 |
Why?
|
| Acupuncture | 3 | 2008 | 90 | 0.440 |
Why?
|
| Diagnosis, Computer-Assisted | 4 | 2014 | 710 | 0.440 |
Why?
|
| Electroconvulsive Therapy | 1 | 2018 | 500 | 0.420 |
Why?
|
| Advisory Committees | 2 | 2014 | 787 | 0.410 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2018 | 895 | 0.400 |
Why?
|
| United States Food and Drug Administration | 4 | 2019 | 1664 | 0.400 |
Why?
|
| Patient Preference | 1 | 2019 | 927 | 0.380 |
Why?
|
| Deep Brain Stimulation | 3 | 2018 | 832 | 0.370 |
Why?
|
| Complementary Therapies | 5 | 2011 | 486 | 0.370 |
Why?
|
| Research Report | 1 | 2014 | 367 | 0.360 |
Why?
|
| Cyclohexanecarboxylic Acids | 5 | 2004 | 140 | 0.360 |
Why?
|
| Peer Review, Research | 1 | 2013 | 340 | 0.350 |
Why?
|
| Paintings | 2 | 2006 | 103 | 0.350 |
Why?
|
| gamma-Aminobutyric Acid | 7 | 2004 | 1141 | 0.340 |
Why?
|
| Cognition Disorders | 5 | 2016 | 3980 | 0.340 |
Why?
|
| Amines | 5 | 2004 | 281 | 0.340 |
Why?
|
| Heart Arrest | 1 | 2020 | 1514 | 0.340 |
Why?
|
| Memory | 2 | 2018 | 2193 | 0.330 |
Why?
|
| Phytotherapy | 2 | 2009 | 296 | 0.330 |
Why?
|
| Cholinesterase Inhibitors | 5 | 2017 | 242 | 0.330 |
Why?
|
| Acupuncture Therapy | 3 | 2008 | 486 | 0.320 |
Why?
|
| Plant Extracts | 3 | 2009 | 497 | 0.320 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 5127 | 0.320 |
Why?
|
| Memory Disorders | 2 | 2015 | 1199 | 0.310 |
Why?
|
| Brain | 24 | 2017 | 27121 | 0.310 |
Why?
|
| Electrodiagnosis | 1 | 2009 | 148 | 0.310 |
Why?
|
| Herbal Medicine | 1 | 2008 | 36 | 0.300 |
Why?
|
| Research Support as Topic | 3 | 2015 | 697 | 0.300 |
Why?
|
| Headache Disorders | 1 | 2010 | 152 | 0.300 |
Why?
|
| Depressive Disorder | 4 | 2015 | 3728 | 0.280 |
Why?
|
| Psychology | 2 | 2006 | 356 | 0.280 |
Why?
|
| Comorbidity | 7 | 2019 | 10508 | 0.270 |
Why?
|
| Congresses as Topic | 3 | 2015 | 803 | 0.260 |
Why?
|
| Mind-Body Relations, Metaphysical | 2 | 2015 | 36 | 0.250 |
Why?
|
| Occupations | 3 | 1998 | 515 | 0.250 |
Why?
|
| Interdisciplinary Communication | 2 | 2008 | 931 | 0.250 |
Why?
|
| Triazines | 7 | 2004 | 311 | 0.250 |
Why?
|
| Double-Blind Method | 15 | 2018 | 12341 | 0.250 |
Why?
|
| Algorithms | 8 | 2018 | 14033 | 0.240 |
Why?
|
| Monitoring, Ambulatory | 4 | 2019 | 354 | 0.240 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 3251 | 0.230 |
Why?
|
| Sleep | 1 | 2020 | 4768 | 0.230 |
Why?
|
| Neurosciences | 1 | 2008 | 367 | 0.230 |
Why?
|
| Perceptual Disorders | 1 | 2006 | 198 | 0.220 |
Why?
|
| Monitoring, Physiologic | 5 | 2020 | 1779 | 0.220 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 1463 | 0.220 |
Why?
|
| Suicidal Ideation | 2 | 2012 | 1447 | 0.210 |
Why?
|
| Endocrine System Diseases | 3 | 2002 | 249 | 0.210 |
Why?
|
| Neural Inhibition | 2 | 2017 | 590 | 0.210 |
Why?
|
| Neurology | 1 | 2010 | 780 | 0.210 |
Why?
|
| Mood Disorders | 3 | 2012 | 1127 | 0.200 |
Why?
|
| Adult | 56 | 2022 | 221210 | 0.200 |
Why?
|
| Communication | 1 | 2016 | 3875 | 0.200 |
Why?
|
| Drug Resistance | 4 | 2014 | 1596 | 0.200 |
Why?
|
| Fructose | 4 | 2004 | 288 | 0.200 |
Why?
|
| Hormones | 3 | 2007 | 869 | 0.200 |
Why?
|
| Acetamides | 2 | 2002 | 256 | 0.200 |
Why?
|
| Societies, Medical | 1 | 2014 | 3905 | 0.190 |
Why?
|
| Academic Medical Centers | 3 | 2015 | 2759 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2000 | 586 | 0.190 |
Why?
|
| History, 20th Century | 6 | 2014 | 2767 | 0.190 |
Why?
|
| Neuroprotective Agents | 4 | 2016 | 957 | 0.190 |
Why?
|
| Transcranial Magnetic Stimulation | 5 | 2018 | 1473 | 0.190 |
Why?
|
| Suicide | 1 | 2012 | 1602 | 0.190 |
Why?
|
| Aptitude | 3 | 1998 | 43 | 0.190 |
Why?
|
| Acceleration | 1 | 2022 | 189 | 0.190 |
Why?
|
| Acetates | 5 | 2004 | 321 | 0.190 |
Why?
|
| Endocrine System | 1 | 2002 | 114 | 0.180 |
Why?
|
| Neuropsychological Tests | 6 | 2016 | 7054 | 0.180 |
Why?
|
| Herb-Drug Interactions | 1 | 2020 | 9 | 0.180 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 3223 | 0.180 |
Why?
|
| GABA Agonists | 1 | 2001 | 105 | 0.180 |
Why?
|
| Heart Atria | 2 | 2023 | 1345 | 0.180 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 4762 | 0.180 |
Why?
|
| Internationality | 2 | 2015 | 1001 | 0.170 |
Why?
|
| Pregnancy Complications | 5 | 2004 | 2947 | 0.160 |
Why?
|
| Clinical Trials as Topic | 10 | 2018 | 8002 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2009 | 2690 | 0.160 |
Why?
|
| Valproic Acid | 1 | 2001 | 443 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5337 | 0.150 |
Why?
|
| Cerebral Cortex | 7 | 2017 | 5779 | 0.150 |
Why?
|
| Analgesics | 2 | 2009 | 1070 | 0.140 |
Why?
|
| Brain Waves | 2 | 2011 | 409 | 0.140 |
Why?
|
| Diethylstilbestrol | 2 | 1994 | 87 | 0.140 |
Why?
|
| Female | 62 | 2023 | 392705 | 0.140 |
Why?
|
| Soman | 1 | 2016 | 2 | 0.140 |
Why?
|
| Visual Perception | 1 | 2006 | 1389 | 0.140 |
Why?
|
| Interprofessional Relations | 2 | 2019 | 990 | 0.140 |
Why?
|
| Male | 57 | 2021 | 360846 | 0.140 |
Why?
|
| Trigeminal Neuralgia | 1 | 1998 | 107 | 0.140 |
Why?
|
| Brain Diseases | 4 | 2018 | 1546 | 0.140 |
Why?
|
| Neurons | 9 | 2016 | 9463 | 0.140 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2001 | 376 | 0.140 |
Why?
|
| Verbal Learning | 1 | 2018 | 463 | 0.130 |
Why?
|
| Financing, Organized | 2 | 2008 | 204 | 0.130 |
Why?
|
| Mental Disorders | 4 | 2019 | 6845 | 0.130 |
Why?
|
| Locus Coeruleus | 1 | 1998 | 230 | 0.130 |
Why?
|
| Drug Interactions | 7 | 2020 | 1416 | 0.130 |
Why?
|
| Convulsants | 4 | 2016 | 70 | 0.130 |
Why?
|
| Heart Diseases | 2 | 2019 | 2781 | 0.130 |
Why?
|
| Syndrome | 1 | 2021 | 3267 | 0.120 |
Why?
|
| Journalism | 1 | 2014 | 7 | 0.120 |
Why?
|
| Iatrogenic Disease | 1 | 1998 | 540 | 0.120 |
Why?
|
| Electricity | 1 | 2015 | 181 | 0.120 |
Why?
|
| Epilepsies, Myoclonic | 1 | 1995 | 85 | 0.120 |
Why?
|
| Pattern Recognition, Automated | 2 | 2012 | 997 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2016 | 2319 | 0.120 |
Why?
|
| Long-Term Care | 1 | 1998 | 633 | 0.110 |
Why?
|
| Foundations | 1 | 2014 | 95 | 0.110 |
Why?
|
| Middle Aged | 36 | 2019 | 220921 | 0.110 |
Why?
|
| Models, Organizational | 2 | 2015 | 546 | 0.110 |
Why?
|
| Anniversaries and Special Events | 1 | 2014 | 95 | 0.110 |
Why?
|
| Pain | 4 | 2015 | 5073 | 0.110 |
Why?
|
| Dyslexia | 2 | 1993 | 208 | 0.110 |
Why?
|
| Depression | 5 | 2016 | 8126 | 0.110 |
Why?
|
| Botulinum Toxins | 1 | 1995 | 189 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 219 | 0.110 |
Why?
|
| Treatment Outcome | 20 | 2018 | 64685 | 0.110 |
Why?
|
| Heart | 2 | 2021 | 4404 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2018 | 1814 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2020 | 8181 | 0.100 |
Why?
|
| Age Factors | 7 | 2014 | 18399 | 0.100 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2009 | 266 | 0.100 |
Why?
|
| Equipment and Supplies | 1 | 2015 | 273 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2021 | 875 | 0.100 |
Why?
|
| Neuropsychiatry | 1 | 2013 | 76 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2017 | 1068 | 0.100 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1995 | 269 | 0.100 |
Why?
|
| Biomedical Engineering | 1 | 2014 | 288 | 0.100 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 1213 | 0.100 |
Why?
|
| Health Care Sector | 1 | 2014 | 195 | 0.100 |
Why?
|
| Pilot Projects | 5 | 2018 | 8633 | 0.100 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2007 | 1111 | 0.090 |
Why?
|
| Phenytoin | 1 | 1992 | 190 | 0.090 |
Why?
|
| Biomedical Technology | 1 | 2014 | 211 | 0.090 |
Why?
|
| Animals | 25 | 2020 | 168475 | 0.090 |
Why?
|
| Hair Color | 2 | 1994 | 131 | 0.090 |
Why?
|
| Remote Sensing Technology | 1 | 2012 | 92 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 2226 | 0.090 |
Why?
|
| Aged | 20 | 2018 | 169310 | 0.090 |
Why?
|
| Spinal Cord Compression | 1 | 2013 | 235 | 0.090 |
Why?
|
| Nursing Homes | 1 | 1998 | 1082 | 0.090 |
Why?
|
| Psychomotor Performance | 2 | 2015 | 1882 | 0.090 |
Why?
|
| Calcinosis | 1 | 2019 | 1469 | 0.090 |
Why?
|
| Nanostructures | 1 | 2015 | 552 | 0.090 |
Why?
|
| Reaction Time | 1 | 2016 | 2089 | 0.090 |
Why?
|
| Sex Factors | 5 | 2014 | 10554 | 0.090 |
Why?
|
| Pregnancy | 9 | 2014 | 29890 | 0.090 |
Why?
|
| Executive Function | 1 | 2018 | 1392 | 0.080 |
Why?
|
| Evidence-Based Medicine | 5 | 2008 | 3688 | 0.080 |
Why?
|
| Respiratory Rate | 1 | 2011 | 176 | 0.080 |
Why?
|
| Engineering | 1 | 2009 | 56 | 0.080 |
Why?
|
| Electronics, Medical | 1 | 2009 | 72 | 0.080 |
Why?
|
| Organotechnetium Compounds | 1 | 1989 | 129 | 0.080 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 982 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 650 | 0.080 |
Why?
|
| Epilepsia Partialis Continua | 1 | 2008 | 18 | 0.080 |
Why?
|
| Psychotherapy | 1 | 2018 | 1647 | 0.080 |
Why?
|
| Government Programs | 2 | 2008 | 279 | 0.080 |
Why?
|
| Computer Communication Networks | 1 | 2011 | 293 | 0.080 |
Why?
|
| Psychometrics | 4 | 2013 | 3065 | 0.080 |
Why?
|
| Toxoplasmosis | 1 | 1989 | 94 | 0.080 |
Why?
|
| Risk | 2 | 2018 | 9610 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2015 | 6019 | 0.080 |
Why?
|
| Theft | 1 | 1988 | 20 | 0.080 |
Why?
|
| Tomography, Optical | 1 | 2009 | 129 | 0.080 |
Why?
|
| Acetylcholinesterase | 2 | 2016 | 156 | 0.080 |
Why?
|
| Evoked Potentials | 2 | 2009 | 1047 | 0.080 |
Why?
|
| Cognition | 2 | 2018 | 6992 | 0.080 |
Why?
|
| Community Mental Health Services | 1 | 1992 | 392 | 0.080 |
Why?
|
| Drug Administration Schedule | 5 | 1999 | 4853 | 0.080 |
Why?
|
| Status Epilepticus | 1 | 2014 | 460 | 0.080 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2014 | 589 | 0.080 |
Why?
|
| Neurotoxins | 1 | 2009 | 240 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2006 | 1702 | 0.080 |
Why?
|
| Anxiety | 3 | 2016 | 4573 | 0.080 |
Why?
|
| Microelectrodes | 1 | 2009 | 306 | 0.080 |
Why?
|
| Electrodes | 2 | 2009 | 614 | 0.080 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 15266 | 0.080 |
Why?
|
| Neurosurgical Procedures | 2 | 2018 | 2072 | 0.080 |
Why?
|
| Attention | 1 | 2018 | 2396 | 0.080 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2008 | 41 | 0.070 |
Why?
|
| Organizational Innovation | 2 | 2008 | 537 | 0.070 |
Why?
|
| Electric Stimulation | 2 | 2005 | 1736 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2014 | 2643 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2015 | 1051 | 0.070 |
Why?
|
| Facial Pain | 1 | 2008 | 120 | 0.070 |
Why?
|
| Drug and Narcotic Control | 1 | 2008 | 144 | 0.070 |
Why?
|
| Legislation, Drug | 1 | 2009 | 214 | 0.070 |
Why?
|
| Actigraphy | 1 | 2011 | 520 | 0.070 |
Why?
|
| Psychiatry | 1 | 2019 | 1693 | 0.070 |
Why?
|
| Amyloid beta-Peptides | 3 | 2016 | 3839 | 0.070 |
Why?
|
| Rats | 9 | 2017 | 23741 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 1989 | 376 | 0.070 |
Why?
|
| Brain Chemistry | 3 | 2012 | 960 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2000 | 2877 | 0.060 |
Why?
|
| Flurothyl | 3 | 2000 | 10 | 0.060 |
Why?
|
| Czech Republic | 2 | 2015 | 74 | 0.060 |
Why?
|
| Herpes Simplex | 1 | 1989 | 478 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 1403 | 0.060 |
Why?
|
| Child | 17 | 2017 | 80158 | 0.060 |
Why?
|
| Recurrence | 1 | 2018 | 8466 | 0.060 |
Why?
|
| Illusions | 1 | 2006 | 61 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 1998 | 1703 | 0.060 |
Why?
|
| Research Design | 4 | 2015 | 6180 | 0.060 |
Why?
|
| Encephalitis | 1 | 1989 | 440 | 0.060 |
Why?
|
| Scalp | 3 | 2014 | 389 | 0.060 |
Why?
|
| Goals | 1 | 2010 | 711 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2021 | 3407 | 0.060 |
Why?
|
| Home Care Services | 1 | 1992 | 648 | 0.060 |
Why?
|
| Prefrontal Cortex | 1 | 2015 | 2220 | 0.060 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 18255 | 0.060 |
Why?
|
| History, Medieval | 2 | 2013 | 62 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2005 | 94 | 0.060 |
Why?
|
| History, 16th Century | 2 | 2013 | 70 | 0.060 |
Why?
|
| New England | 1 | 2008 | 1054 | 0.060 |
Why?
|
| Drug Therapy, Combination | 4 | 2011 | 6312 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2009 | 10766 | 0.060 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 1994 | 2518 | 0.060 |
Why?
|
| Young Adult | 5 | 2018 | 59260 | 0.060 |
Why?
|
| Adolescent | 18 | 2017 | 88326 | 0.060 |
Why?
|
| History, 17th Century | 2 | 2013 | 108 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 1994 | 2691 | 0.060 |
Why?
|
| Menarche | 1 | 2007 | 532 | 0.060 |
Why?
|
| History, Ancient | 2 | 2013 | 212 | 0.060 |
Why?
|
| History, 18th Century | 2 | 2013 | 207 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2009 | 740 | 0.060 |
Why?
|
| Dietary Supplements | 2 | 2009 | 3415 | 0.060 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2004 | 46 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 14608 | 0.060 |
Why?
|
| Alcoholism | 1 | 1994 | 1973 | 0.060 |
Why?
|
| Heart Conduction System | 1 | 2009 | 1007 | 0.060 |
Why?
|
| Prognosis | 3 | 2018 | 29629 | 0.050 |
Why?
|
| Drug Tolerance | 2 | 2004 | 367 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 8527 | 0.050 |
Why?
|
| Motor Skills | 2 | 1998 | 521 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2006 | 364 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2009 | 1440 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2018 | 36426 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 150 | 0.050 |
Why?
|
| Neurosurgery | 1 | 2009 | 679 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2005 | 432 | 0.050 |
Why?
|
| Magnetics | 1 | 2005 | 599 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2006 | 10212 | 0.050 |
Why?
|
| History, 19th Century | 2 | 2013 | 720 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2004 | 446 | 0.050 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2000 | 74 | 0.050 |
Why?
|
| United States | 9 | 2019 | 72340 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 15936 | 0.050 |
Why?
|
| Diagnosis, Differential | 4 | 2004 | 12973 | 0.050 |
Why?
|
| Action Potentials | 1 | 2009 | 1834 | 0.050 |
Why?
|
| Incidence | 1 | 2020 | 21355 | 0.050 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2001 | 116 | 0.050 |
Why?
|
| Risk Management | 1 | 2005 | 558 | 0.050 |
Why?
|
| Hospital Administration | 1 | 2005 | 353 | 0.050 |
Why?
|
| Brachial Plexus | 1 | 1982 | 167 | 0.050 |
Why?
|
| Family | 1 | 1992 | 3195 | 0.050 |
Why?
|
| Device Approval | 1 | 2002 | 163 | 0.050 |
Why?
|
| Panic Disorder | 2 | 1995 | 613 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2006 | 703 | 0.040 |
Why?
|
| Stroke | 1 | 2003 | 9758 | 0.040 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2000 | 68 | 0.040 |
Why?
|
| Contractile Proteins | 1 | 2001 | 240 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 2199 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 1486 | 0.040 |
Why?
|
| Immunotoxins | 1 | 2000 | 175 | 0.040 |
Why?
|
| Obstetric Labor Complications | 1 | 1982 | 236 | 0.040 |
Why?
|
| Biological Availability | 1 | 2001 | 390 | 0.040 |
Why?
|
| Phenethylamines | 1 | 2000 | 95 | 0.040 |
Why?
|
| Pentylenetetrazole | 2 | 2015 | 71 | 0.040 |
Why?
|
| Reference Values | 2 | 1998 | 4920 | 0.040 |
Why?
|
| Piracetam | 3 | 2004 | 88 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 1667 | 0.040 |
Why?
|
| Caregivers | 1 | 1992 | 2238 | 0.040 |
Why?
|
| Brain Mapping | 2 | 2009 | 6635 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2009 | 2180 | 0.040 |
Why?
|
| Self Concept | 1 | 2005 | 1045 | 0.040 |
Why?
|
| Menopause | 1 | 2007 | 1646 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2021 | 638 | 0.040 |
Why?
|
| Placebos | 2 | 1995 | 1667 | 0.040 |
Why?
|
| Software | 2 | 2007 | 4434 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2001 | 542 | 0.040 |
Why?
|
| Pons | 1 | 2000 | 240 | 0.040 |
Why?
|
| Prosencephalon | 1 | 2000 | 305 | 0.040 |
Why?
|
| Medulla Oblongata | 1 | 2000 | 248 | 0.040 |
Why?
|
| Amnesia | 2 | 2015 | 257 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 2079 | 0.040 |
Why?
|
| Isoxazoles | 3 | 2004 | 232 | 0.040 |
Why?
|
| Personality Inventory | 2 | 1999 | 1019 | 0.040 |
Why?
|
| Mice, Inbred DBA | 1 | 2019 | 621 | 0.040 |
Why?
|
| Plant Proteins | 1 | 2000 | 370 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2020 | 1541 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39106 | 0.040 |
Why?
|
| Muscarinic Antagonists | 2 | 2009 | 135 | 0.040 |
Why?
|
| Kainic Acid | 1 | 1998 | 203 | 0.040 |
Why?
|
| X Chromosome | 1 | 2001 | 816 | 0.040 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 14665 | 0.040 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 20100 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2009 | 1958 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 1386 | 0.040 |
Why?
|
| Women's Health | 1 | 2007 | 2065 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 1999 | 299 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1994 | 702 | 0.040 |
Why?
|
| Bereavement | 1 | 2001 | 308 | 0.040 |
Why?
|
| Emotions | 1 | 2009 | 2739 | 0.040 |
Why?
|
| Drug Utilization Review | 1 | 1998 | 248 | 0.040 |
Why?
|
| Sensation | 1 | 1999 | 337 | 0.040 |
Why?
|
| Pyridostigmine Bromide | 1 | 2016 | 32 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2011 | 2578 | 0.040 |
Why?
|
| Alzheimer Disease | 2 | 2016 | 8601 | 0.030 |
Why?
|
| Chemical Warfare Agents | 1 | 2016 | 19 | 0.030 |
Why?
|
| Auditory Pathways | 1 | 1999 | 237 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 23996 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 1625 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2001 | 1134 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1982 | 2224 | 0.030 |
Why?
|
| Myoclonic Epilepsy, Juvenile | 1 | 2015 | 13 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2009 | 3600 | 0.030 |
Why?
|
| Dosage Forms | 1 | 1995 | 56 | 0.030 |
Why?
|
| Prevalence | 3 | 2019 | 15733 | 0.030 |
Why?
|
| North America | 1 | 2019 | 1276 | 0.030 |
Why?
|
| Telephone | 1 | 1999 | 627 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2018 | 543 | 0.030 |
Why?
|
| Respiratory Mechanics | 1 | 1999 | 699 | 0.030 |
Why?
|
| Equipment Design | 2 | 2015 | 3511 | 0.030 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2004 | 1070 | 0.030 |
Why?
|
| Risk Factors | 4 | 2018 | 74213 | 0.030 |
Why?
|
| Child Development | 1 | 1986 | 2306 | 0.030 |
Why?
|
| Respiration | 1 | 2001 | 1656 | 0.030 |
Why?
|
| Telemedicine | 1 | 2012 | 3052 | 0.030 |
Why?
|
| Compulsive Behavior | 1 | 2015 | 117 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2016 | 903 | 0.030 |
Why?
|
| Prostheses and Implants | 2 | 1998 | 1271 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 273 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1999 | 783 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 659 | 0.030 |
Why?
|
| Muscle Contraction | 2 | 1999 | 1201 | 0.030 |
Why?
|
| Hippocampus | 2 | 2017 | 3766 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 1555 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2020 | 1132 | 0.030 |
Why?
|
| Family Practice | 1 | 1997 | 512 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 2001 | 1423 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1995 | 554 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 1998 | 592 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2014 | 26202 | 0.030 |
Why?
|
| Video Recording | 1 | 1999 | 967 | 0.030 |
Why?
|
| Brain Stem | 1 | 1999 | 858 | 0.030 |
Why?
|
| Gene Expression | 1 | 2006 | 7581 | 0.030 |
Why?
|
| Drug Utilization | 1 | 1999 | 1188 | 0.030 |
Why?
|
| Biophysics | 1 | 2014 | 380 | 0.030 |
Why?
|
| Behavior, Animal | 2 | 2013 | 1878 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2000 | 1166 | 0.030 |
Why?
|
| Exercise | 1 | 2010 | 5890 | 0.030 |
Why?
|
| Huntington Disease | 1 | 2000 | 1144 | 0.030 |
Why?
|
| Gonadotropins | 1 | 1994 | 241 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 1995 | 212 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2007 | 620 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 1996 | 485 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2009 | 4687 | 0.030 |
Why?
|
| Menstruation | 1 | 1994 | 307 | 0.020 |
Why?
|
| Quality Control | 2 | 2005 | 832 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 1992 | 134 | 0.020 |
Why?
|
| Time Factors | 5 | 2016 | 39969 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2016 | 1561 | 0.020 |
Why?
|
| Prolactin | 1 | 1994 | 625 | 0.020 |
Why?
|
| Terminology as Topic | 2 | 2004 | 1530 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2016 | 8321 | 0.020 |
Why?
|
| Capsules | 1 | 1992 | 191 | 0.020 |
Why?
|
| Stomach | 1 | 1996 | 696 | 0.020 |
Why?
|
| Limbic System | 1 | 1994 | 419 | 0.020 |
Why?
|
| Role | 1 | 1992 | 176 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 1994 | 554 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 999 | 0.020 |
Why?
|
| Markov Chains | 1 | 2014 | 966 | 0.020 |
Why?
|
| Motion | 1 | 2014 | 779 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 1982 | 1964 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2004 | 3067 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2496 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 12690 | 0.020 |
Why?
|
| Aggression | 1 | 2015 | 750 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 9469 | 0.020 |
Why?
|
| Electric Power Supplies | 1 | 2011 | 96 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 728 | 0.020 |
Why?
|
| Microfluidics | 1 | 2015 | 653 | 0.020 |
Why?
|
| Physician's Role | 1 | 1997 | 917 | 0.020 |
Why?
|
| Universities | 1 | 2015 | 993 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 1992 | 412 | 0.020 |
Why?
|
| Sugar Acids | 1 | 1989 | 24 | 0.020 |
Why?
|
| Terminal Care | 1 | 2001 | 1761 | 0.020 |
Why?
|
| Atropine | 1 | 2009 | 244 | 0.020 |
Why?
|
| Reading | 1 | 1993 | 531 | 0.020 |
Why?
|
| Career Choice | 1 | 1996 | 756 | 0.020 |
Why?
|
| Massachusetts | 2 | 2008 | 8833 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 1999 | 1670 | 0.020 |
Why?
|
| Reproduction | 1 | 1994 | 645 | 0.020 |
Why?
|
| Dementia | 1 | 2004 | 2689 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1123 | 0.020 |
Why?
|
| Biofeedback, Psychology | 1 | 2010 | 116 | 0.020 |
Why?
|
| Technetium | 1 | 1989 | 317 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2009 | 318 | 0.020 |
Why?
|
| Catheterization | 2 | 2009 | 1428 | 0.020 |
Why?
|
| Social Behavior | 1 | 2015 | 1135 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 1990 | 510 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2017 | 42232 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 2010 | 181 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 1436 | 0.020 |
Why?
|
| Hypothalamus | 1 | 1994 | 999 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1999 | 4160 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2226 | 0.020 |
Why?
|
| Magnetoencephalography | 1 | 2012 | 636 | 0.020 |
Why?
|
| Progesterone | 1 | 1993 | 742 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2011 | 847 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1982 | 5914 | 0.020 |
Why?
|
| Acupuncture Analgesia | 1 | 2008 | 63 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3810 | 0.020 |
Why?
|
| Motor Activity | 1 | 1998 | 2715 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 1999 | 11076 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 3530 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 1998 | 1157 | 0.020 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2008 | 209 | 0.020 |
Why?
|
| Receptors, Muscarinic | 1 | 2007 | 157 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1998 | 2775 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 665 | 0.020 |
Why?
|
| Drug Approval | 2 | 2004 | 814 | 0.020 |
Why?
|
| Videotape Recording | 1 | 1988 | 337 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2000 | 3049 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2006 | 113 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 3713 | 0.020 |
Why?
|
| Echinacea | 1 | 2005 | 5 | 0.020 |
Why?
|
| Serenoa | 1 | 2005 | 11 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5247 | 0.020 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 6484 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 473 | 0.020 |
Why?
|
| Ginkgo biloba | 1 | 2005 | 27 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2007 | 238 | 0.020 |
Why?
|
| Estrogens | 1 | 1993 | 1522 | 0.020 |
Why?
|
| Garlic | 1 | 2005 | 28 | 0.020 |
Why?
|
| Health Status | 1 | 1999 | 4077 | 0.020 |
Why?
|
| Hypericum | 1 | 2005 | 58 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 4352 | 0.020 |
Why?
|
| Data Collection | 1 | 1994 | 3322 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 16990 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 1972 | 0.020 |
Why?
|
| Oxygen | 1 | 1996 | 4227 | 0.020 |
Why?
|
| Pain Measurement | 2 | 2009 | 3551 | 0.010 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2006 | 311 | 0.010 |
Why?
|
| Length of Stay | 1 | 1998 | 6426 | 0.010 |
Why?
|
| Credentialing | 1 | 2005 | 116 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2019 | 9319 | 0.010 |
Why?
|
| Age Distribution | 1 | 2010 | 2879 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 2017 | 80647 | 0.010 |
Why?
|
| Drug Contamination | 1 | 2005 | 152 | 0.010 |
Why?
|
| Leadership | 1 | 2014 | 1385 | 0.010 |
Why?
|
| Americas | 1 | 2004 | 111 | 0.010 |
Why?
|
| Phenotype | 2 | 2018 | 16592 | 0.010 |
Why?
|
| Epilepsy, Absence | 1 | 2004 | 49 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2008 | 866 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1992 | 4021 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 882 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22176 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2006 | 481 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 2004 | 236 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 186 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2018 | 6567 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 2421 | 0.010 |
Why?
|
| Clinical Medicine | 1 | 2004 | 145 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2007 | 1202 | 0.010 |
Why?
|
| Neoplasms | 1 | 1992 | 22173 | 0.010 |
Why?
|
| Endopeptidases | 1 | 2006 | 774 | 0.010 |
Why?
|
| Hospitalization | 1 | 2022 | 10721 | 0.010 |
Why?
|
| Prospective Studies | 4 | 2019 | 54423 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 2004 | 470 | 0.010 |
Why?
|
| Neural Pathways | 1 | 1993 | 3060 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2011 | 6345 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2007 | 3597 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2001 | 329 | 0.010 |
Why?
|
| Life Style | 1 | 1993 | 3917 | 0.010 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2000 | 27 | 0.010 |
Why?
|
| Boston | 1 | 2014 | 9327 | 0.010 |
Why?
|
| Receptors, Catecholamine | 1 | 2000 | 6 | 0.010 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 1 | 2000 | 18 | 0.010 |
Why?
|
| Australia | 1 | 2004 | 1250 | 0.010 |
Why?
|
| Sensory Thresholds | 1 | 2001 | 377 | 0.010 |
Why?
|
| Malpractice | 1 | 2005 | 556 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 1995 | 4948 | 0.010 |
Why?
|
| Infant | 2 | 2017 | 36193 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13510 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 17904 | 0.010 |
Why?
|
| Denervation | 1 | 2000 | 265 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2007 | 1250 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 1648 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 5035 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2001 | 400 | 0.010 |
Why?
|
| Anesthesia | 1 | 1990 | 1595 | 0.010 |
Why?
|
| Nerve Fibers | 1 | 2001 | 708 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2005 | 2426 | 0.010 |
Why?
|
| Schools, Medical | 1 | 2004 | 879 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 5791 | 0.010 |
Why?
|
| Biopsy | 1 | 1989 | 6766 | 0.010 |
Why?
|
| Reflex | 1 | 1999 | 376 | 0.010 |
Why?
|
| Awareness | 1 | 2001 | 648 | 0.010 |
Why?
|
| Thalamus | 1 | 1983 | 1047 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2820 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 3306 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41495 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1992 | 4481 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 1998 | 58984 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1996 | 6228 | 0.010 |
Why?
|
| Gastric Balloon | 1 | 1996 | 36 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2001 | 952 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1998 | 15633 | 0.010 |
Why?
|
| Sphenoid Bone | 1 | 1996 | 177 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1999 | 2264 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2007 | 5112 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 1993 | 4575 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2001 | 8481 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2000 | 1787 | 0.010 |
Why?
|
| Obesity | 1 | 1996 | 12947 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 7237 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 4111 | 0.010 |
Why?
|
| Clonazepam | 1 | 1993 | 135 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 15601 | 0.010 |
Why?
|
| Vietnam | 1 | 1993 | 409 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 81539 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1983 | 3424 | 0.010 |
Why?
|
| Educational Status | 1 | 1999 | 2522 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2001 | 2639 | 0.010 |
Why?
|
| Curriculum | 1 | 2004 | 3743 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2007 | 7859 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1993 | 916 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 5079 | 0.010 |
Why?
|
| Patient Participation | 1 | 1998 | 1445 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2004 | 4793 | 0.000 |
Why?
|
| Energy Intake | 1 | 1996 | 2134 | 0.000 |
Why?
|
| Registries | 1 | 2004 | 8225 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 7391 | 0.000 |
Why?
|
| Patient Satisfaction | 1 | 1998 | 3462 | 0.000 |
Why?
|
| Weight Loss | 1 | 1996 | 2684 | 0.000 |
Why?
|
| Aging | 1 | 2001 | 8710 | 0.000 |
Why?
|
| Radiography | 1 | 1993 | 6965 | 0.000 |
Why?
|
| Veterans | 1 | 1993 | 2649 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1983 | 20568 | 0.000 |
Why?
|